Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary) ; Prednisone
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAR
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 24 Jan 2019 According to a Vifor Pharma media release, the company has withdrawn the Conditional Marketing Approval Application of avacopan for the treatment of ANCA-associated vasculitis which was submitted earlier based on data comprising 12 week dosing on around 67 patients from this trial.
    • 16 Jun 2018 Results evaluating the Effect of Avacopan (Ccx168) on plasma complement levels were presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR)
    • 23 May 2018 According to a ChemoCentryx media release, data from this study will be presented at the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, in collaboration with the Danish Society of Nephrology (DSN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top